{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:22:07Z","timestamp":1784949727515,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jgar.2022.07.022","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T18:29:34Z","timestamp":1659896974000},"page":"52-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study"],"prefix":"10.1016","volume":"31","author":[{"given":"Maria Mercedes","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3406-7014","authenticated-orcid":false,"given":"Daniele","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Teyssou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-7114","authenticated-orcid":false,"given":"Jos\u00e9 Ram\u00f3n","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidonie","family":"Lambert-Niclot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-8999","authenticated-orcid":false,"given":"Anne Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.07.022_bib0001","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2022.07.022_bib0002","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7326\/L16-0091","article-title":"Update of survival for persons with HIV infection in Denmark","volume":"165","author":"Lohse","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2022.07.022_bib0003","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services (last update 20 January 2022). https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf."},{"key":"10.1016\/j.jgar.2022.07.022_bib0004","unstructured":"European AIDS Clinical Society. Guidelines: version 11.0 2021. https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf."},{"key":"10.1016\/j.jgar.2022.07.022_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir\u2013lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2022.07.022_bib0006","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.022_bib0007","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.07.022_bib0008","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.022_bib0009","author":"Llibre","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.022_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.022_bib0011","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/hiv.12611","article-title":"Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication","volume":"19","author":"Borghetti","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.07.022_bib0012","first-page":"410","article-title":"Single tablet regimen with abacavir\/lamivudine\/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study","volume":"27","author":"Baldin","year":"2019","journal-title":"Le Infez Med"},{"key":"10.1016\/j.jgar.2022.07.022_bib0013","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI) 2019","article-title":"Factors associated with therapeutic failure of 2 drug regimens (DAT'AIDS Cohort)","author":"Allavena","year":"2019"},{"key":"10.1016\/j.jgar.2022.07.022_bib0014","series-title":"HIV Glasgow Conference 2020","article-title":"Dual HIV treatment in experienced HIV patients","author":"Battagin","year":"2020"},{"key":"10.1016\/j.jgar.2022.07.022_bib0015","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Effect of past virological failure on dolutegravir\u00a0+\u00a0lamivudine as maintenance regimen","author":"Gagliardini","year":"2020"},{"key":"10.1016\/j.jgar.2022.07.022_bib0016","series-title":"HIV Glasgow Conference 2020","article-title":"Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG)\u00a0+\u00a0lamivudine (3TC) in ART na\u00efve and pre-treated people living with HIV in Germany","author":"Postel","year":"2020"},{"key":"10.1016\/j.jgar.2022.07.022_bib0017","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.022_bib0018","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jac\/dkz009","article-title":"Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: Long-term data from clinical practice","volume":"74","author":"Baldin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.07.022_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-018-3666-8","article-title":"Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 11 Medical and Health Sciences 1103 Clinical Sci","volume":"19","author":"Borghetti","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.022_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3851\/IMP3270","article-title":"A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients","volume":"24","author":"Ciccullo","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2022.07.022_bib0021","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/QAI.0000000000002378","article-title":"Simplification to high genetic barrier 2-drug regimens in people living with HIV harboring 4-class resistance enrolled in the PRESTIGIO Registry","volume":"84","author":"Canetti","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.07.022_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105893","article-title":"Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients","volume":"55","author":"Galizzi","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.07.022_bib0023","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/hiv.13062","article-title":"Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice","volume":"22","author":"Armenia","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.07.022_bib0024","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/hiv.13146","article-title":"Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: data from real-life ODOACRE cohort","volume":"22","author":"Fabbiani","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.07.022_bib0025","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dki038","article-title":"The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance","volume":"55","author":"No\u00eb","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.07.022_bib0026","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1468-1293.2002.00101.x","article-title":"The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response","volume":"3","author":"Miller","year":"2002","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.07.022_bib0027","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir!lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.07.022_bib0028","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkaa479","article-title":"Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study","volume":"76","author":"Rial-Crestelo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.07.022_bib0029","unstructured":"G, Blick, E., Cerreta, G., Mancini1 AC. SOLAR 3D: a prospective comparative study switching from 3- or 4-drug ART to DTG\/3TC for maintenance of viral suppression in the setting of current and historical M184V\/I and prior virologic failures: 48 week primary endpoint results. In: EACS 2021 Oct 27-30., 2021."},{"key":"10.1016\/j.jgar.2022.07.022_bib0030","unstructured":"Hocqueloux L, Allavena C, Secher S, Makinson A, Rey D, Huleux T, et\u00a0al. Archived mutation M184V does not increase virologic failure during maintenance therapy with dolutegravir\u00a0+\u00a0lamivudine in the French DAT'AIDS cohort. EACS, 27\u201330 October 2021."},{"key":"10.1016\/j.jgar.2022.07.022_bib0031","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2022.07.022_bib0032","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000002787","article-title":"Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding","author":"Ciccullo","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.07.022_bib0033","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jviromet.2011.03.014","article-title":"Performance evaluation of the COBAS\/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study","volume":"173","author":"Paba","year":"2011","journal-title":"J Virol Methods"},{"key":"10.1016\/j.jgar.2022.07.022_bib0034","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/QAI.0b013e3182099891","article-title":"Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep\/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays","volume":"56","author":"Sire","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.07.022_bib0035","article-title":"Comparison of the Aptima HIV-1 Quant Dx assay with the COBAS AmpliPrep\/COBAS TaqMan HIV-1 v2.0 Test for HIV-1 viral load quantification in plasma samples from HIV-1\u2013infected patients","volume":"1","author":"Longo","year":"2018","journal-title":"Heal Sci Reports"},{"key":"10.1016\/j.jgar.2022.07.022_bib0036","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.07.022_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgar.2022.01.018","article-title":"Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study","author":"Gagliardini","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2022.07.022_bib0038","doi-asserted-by":"crossref","first-page":"ofab103","DOI":"10.1093\/ofid\/ofab103","article-title":"Nucleoside reverse-transcriptase inhibitor resistance mutations predict virological failure in human immunodeficiency virus-positive patients during lamivudine plus dolutegravir maintenance therapy in clinical practice","volume":"8","author":"Borghetti","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.022_bib0039","article-title":"Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients","author":"Palich","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2022.07.022_bib0040","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/JVI.79.3.1975-1980.2005","article-title":"G\u2013>A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo","volume":"79","author":"Kieffer","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jgar.2022.07.022_bib0041","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cmi.2015.10.004","article-title":"Contribution of APOBEC3G\/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants","volume":"22","author":"Noguera-Julian","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2022.07.022_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2018.04.001","article-title":"Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment","author":"Armenia","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jgar.2022.07.022_bib0043","first-page":"855","article-title":"Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir\/emtricitabine\/rilpivirine single-tablet regimen","volume":"72","author":"Armenia","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.07.022_bib0044","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/QAI.0000000000002898","article-title":"Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy","volume":"89","author":"Dijkstra","year":"2022","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:01Z","timestamp":1761991261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522001898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":44,"alternative-id":["S2213716522001898"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.07.022","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}